Description of Procedure or Service

Therapeutic intervention to treat varicose veins/venous insufficiency may be performed using embolization, ablation or sclerotherapy.

This medical policy addresses the treatment of pelvic varices:

1. For pelvic congestion syndrome and
2. As part of treatment of lower extremity venous insufficiency.

Varices in the veins that originate in the pelvis may include the ovarian and iliac veins. The ovarian veins in women are also referred to as the gonadal veins. The gonadal veins in men are known as testicular or internal spermatic veins. Gonadal veins drain into the renal vein and inferior vena cava from the testicle or ovary. This policy does not address treatment of the gonadal vein in men for varicose veins of the scrotum (varicocele).

Pelvic congestion syndrome

Pelvic congestion syndrome (also called pelvic venous incompetence) is a condition described as chronic pelvic discomfort exacerbated by prolonged standing and associated with dyspareunia. The syndrome occurs during the reproductive years, and pain is often greater before or during menses. The underlying etiology is unclear, but many women thought to have pelvic congestion syndrome have dilation, incompetence and reflux of the pelvic veins. Hormonal and/or anatomic factors are thought to lead to venous insufficiency of the ovarian and/or internal iliac veins, leading to periovarian pelvic varicosities.

As there are many etiologies of chronic pelvic pain, pelvic congestion syndrome is often a diagnosis of exclusion, with the identification of varices using a variety of imaging methods, such as magnetic resonance imaging (MRI), computed tomography (CT) scanning, or contrast venography. However, not all women with pelvic venous reflux experience chronic pelvic pain.

Initial treatment of pelvic congestion syndrome includes medical therapy (e.g., nonsteroidal anti-inflammatory drugs) and hormonal therapy. For those who fail initial therapy, open surgical and laparoscopic ligation of pelvic varices has been considered. Embolization therapy of the ovarian and internal iliac veins has been proposed as an alternative to surgical ovarian vein ligation. Vein embolization can be performed using a variety of materials including coils, glue, and gel foam.

Treatment of pelvic varices for lower extremity venous insufficiency

Pelvic venous reflux into lower extremity leg varices has been suggested as a cause of recurrent varicose veins in the lower extremity, often in the setting of pelvic congestion syndrome. It has been proposed that in certain patients, the treatment of lower extremity varicose veins should also include treatment of the pelvic varices.
Ovarian and Internal Iliac Vein Embolization, Ablation and Sclerotherapy

**Regulatory Status**
Vein embolization is a surgical procedure and, as such, is not subject to regulation by the U.S. Food and Drug Administration (FDA). Various materials (e.g., coils, vascular plugs, glue, liquid embolic agents, gel foam) would be used to embolize the vein(s), and they would be subject to FDA regulation. Several products have been cleared for marketing by FDA through the 510(k) process for embolization techniques (e.g., Embosphere® Microspheres [South Jordan, UT], Cook Incorporated Polyvinyl Alcohol Foam Embolization Particles [Bloomington, IN]) and/or embolization of hypervascular tumors and arteriovenous malformations (e.g., Contour® Emboli PVA [Marlborough, MA]). Several embolization delivery systems have also been cleared via the 510(k) process for arterial and venous embolization in the peripheral vasculature featuring vascular plugs (e.g., ArtVentive Medical Group, Inc. Endoluminal Occlusion System [EOSTM]) or coils (e.g., Cook Incorporated MReye® Flipper®). FDA product code: KRD.

In November 2004, the sclerosant agent Sotradecol® (sodium tetradecyl sulfate injection) was approved by the FDA for use in the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves (ANDA 040541).

This policy does not address isolated treatment of male gonadal veins or varicose veins of the lower extremities. Refer to policy titled “Varicose Veins of the Lower Extremities, Treatment for”.

***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician.***

**Policy**

Ovarian and internal iliac vein embolization, ablation or sclerotherapy is considered investigational as a treatment of pelvic congestion syndrome and as part of treatment of lower extremity varicose veins. BCBSNC does not provide coverage for investigational services or procedures.

**Benefits Application**

This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member’s benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy.

**When Ovarian and Internal Iliac Vein Embolization is covered**

Not applicable.

**When Ovarian and Internal Iliac Vein Embolization is not covered**

Embolization, ablation or sclerotherapy of ovarian veins and internal iliac veins is considered investigational as a treatment of pelvic congestion syndrome and as part of treatment of lower extremity varicose veins.

Embolization, ablation or sclerotherapy of any other pelvic veins is considered investigational as a treatment of pelvic congestion syndrome and as part of treatment of lower extremity varicose veins.
Ovarian and Internal Iliac Vein Embolization, Ablation and Sclerotherapy

Policy Guidelines

There are no generally accepted, well-defined clinical criteria for the diagnosis of pelvic congestion syndrome, reflecting the residual uncertainty that there is a causal relationship between pelvic vein incompetence and chronic pelvic pain. Since it is predominantly observed in multiparous women of reproductive age, it suggests both a mechanical and a hormonal mechanism. The data supporting the diagnosis and treatment of pelvic vein incompetence in the presence of chronic pelvic pain are limited and of variable quality, and higher quality research is required to thoroughly address the research question. Although some research has shown that treatment of pelvic varices provides symptomatic relief in some women, the studies are small case series from which conclusions cannot be drawn with certainty.

Likewise, there is insufficient good quality research to show that embolization, ablation, or sclerotherapy of pelvic varices improves long term health outcomes in the treatment of lower extremity varicose veins.

Billing/Coding/Physician Documentation Information

This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at www.bcbsnc.com. They are listed in the Category Search on the Medical Policy search page.

There are no specific CPT codes for this procedure. The following nonspecific CPT codes may be used: 36012 and 37241.

ICD-10 diagnosis codes: I86.2, N94.89

CPT provides clarification regarding the intended use for 37241 as follows:
• For sclerosis of veins or endovenous ablation of incompetent extremity veins, use 36468–36479
• Do not report 37241 in conjunction with 36468, 36470, 36471, 36475–36479, 75894, 75898 in the same surgical field

Examples of intended use of 37241 (not an all-inclusive list):
• Embolization/occlusion of gastric/esophageal varices;
• Embolization/occlusion of varicoceles;
• Embolization/occlusion of incompetent ovarian vein for pelvic congestion syndrome;
• Embolization/occlusion of patent perforators siphoning flow from dialysis access fistula;
• Embolization/occlusion of patent perforators siphoning flow from lower extremity venous bypass grafts;
• Injection/occlusion/embolization of vascular malformations that are primarily venous;
• Injection/occlusion/embolization of vascular malformations that are primarily lymphatic.

BCBSNC may request medical records for determination of medical necessity. When medical records are requested, letters of support and/or explanation are often useful, but are not sufficient documentation unless all specific information needed to make a medical necessity determination is included.

Scientific Background and Reference Sources


Ovarian and Internal Iliac Vein Embolization, Ablation and Sclerotherapy


Medical Director review – July 2018


Ovarian and Internal Iliac Vein Embolization, Ablation and Sclerotherapy


**Policy Implementation/Update Information**

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>6/8/10</td>
<td>Coding information added to the Billing/Coding section. There is no specific CPT code for this procedure, however CPT 75894 and 37204 might be used. (adn)</td>
</tr>
<tr>
<td>6/22/10</td>
<td>Policy Number(s) removed (amw)</td>
</tr>
<tr>
<td>4/16/13</td>
<td>Specialty Matched Consultant Advisory Panel review 3/20/13. No change to Policy statement. (sk)</td>
</tr>
<tr>
<td>7/1/13</td>
<td>Reference added. Updated Billing/Coding section, adding code 36012. No change to Policy statement. ICD-10 diagnosis codes added to Billing/Coding section. (sk)</td>
</tr>
<tr>
<td>12/31/13</td>
<td>Coding update. CPT 37204 deleted. CPT 37243 added. (sk)</td>
</tr>
<tr>
<td>8/26/14</td>
<td>Reference added. No change to Policy statement. (sk)</td>
</tr>
<tr>
<td>7/28/15</td>
<td>Reference added. Related Guideline removed. (sk)</td>
</tr>
<tr>
<td>9/7/18</td>
<td>Policy name changed from “Ovarian and Internal Iliac Vein Embolization” to “Ovarian, Internal Iliac and Gonadal Vein Embolization, Ablation and Sclerotherapy”. Description</td>
</tr>
</tbody>
</table>

An Independent Licensee of the Blue Cross and Blue Shield Association
Ovarian and Internal Iliac Vein Embolization, Ablation and Sclerotherapy

section updated with revisions for pelvic congestion syndrome and addition of information regarding varicocele. NOTE: This policy does not address varicose veins of the lower extremities. Refer to policy titled “Varicose Veins of the Lower Extremities, Treatment for”. Policy statement revised to read: **Ovarian, Internal Iliac and Gonadal Vein Embolization, Ablation and Sclerotherapy is considered investigational as a treatment of Pelvic Congestion Syndrome or Varicoceles.** When Not Covered section revised to read: Embolization, ablation or sclerotherapy of ovarian veins, internal iliac veins, or gonadal veins is considered investigational as a treatment of pelvic congestion syndrome or varicoceles. Policy Guidelines updated. Added codes I86.1, I86.2 to Billing/Coding section. Additional coding instructions added to Billing/Coding section. References added.

11/9/18 Policy statement clarified to read: “Ovarian, Internal Iliac and Gonadal Vein Embolization, Ablation or Sclerotherapy is considered investigational as a treatment of Pelvic Congestion Syndrome and as part of treatment of lower extremity varicose veins.” (an)

4/16/19 Reference added. Specialty Matched Consultant Advisory Panel review 3/20/2019. No change to policy statement. (an)

12/31/19 Policy name changed from “Ovarian, Internal Iliac and Gonadal Vein Embolization, Ablation and Sclerotherapy” to “Ovarian and Internal Iliac Vein Embolization, Ablation and Sclerotherapy”. Policy guideline and description section updated. Policy updated to no longer address treatment of the gonadal vein in men with varicocele. Removed I86.1 from coding section. (eel)

3/24/20 Description section updated with definition of gonadal veins. When not covered section clarified with pelvic veins. No change to policy statement. (eel)

5/26/20 Reference added. Specialty Matched Consultant Advisory Panel review 3/18/2020. No change to policy statement. (eel)


Medical policy is not an authorization, certification, explanation of benefits or a contract. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the group contract and subscriber certificate that is in effect at the time services are rendered. This document is solely provided for informational purposes only and is based on research of current medical literature and review of common medical practices in the treatment and diagnosis of disease. Medical practices and knowledge are constantly changing and BCBSNC reserves the right to review and revise its medical policies periodically.